Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-5.38% $1.760
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 119.19 mill |
EPS: | -0.0100 |
P/E: | -176.00 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 67.72 mill |
Avg Daily Volume: | 0.922 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Buy | |
DE: | Strong Sell | |
P/E: | Strong Buy | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -176.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-29.94x |
Company: PE -176.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.581 - 1.939 ( +/- 10.17%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 0 | |
2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
INSIDER POWER |
---|
64.81 |
Last 98 transactions |
Buy: 4 891 928 | Sell: 1 103 909 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.760 (-5.38% ) |
Volume | 0.585 mill |
Avg. Vol. | 0.922 mill |
% of Avg. Vol | 63.45 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.